The transaction will broaden access to cost-effective and innovative laboratory services in Ohio. After the acquisition's close, providers and patients will benefit from access to Quest's industry-leading test menu, network of patient service sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our labo ...

文章核心观点 - 美国诊断公司Quest Diagnostics与明尼苏达州的非营利性医疗系统Allina Health达成协议,收购Allina Health的部分实验室资产 [1][2][3] - 此次收购有助于Quest Diagnostics在明尼苏达州及其周边地区扩大其独特且成本高效的实验室服务 [2] - 此次交易有利于Allina Health将非营利资源重新投资,以支持其为不同社区提供优质和可负担的实验室服务的承诺 [4] - 此次交易符合Quest Diagnostics和Allina Health的共同利益,即帮助各界从优质、创新和可负担的实验室服务中获益 [5] - 此次收购是Quest Diagnostics通过收购实验室资产来实现增长战略的一部分 [6][8] 行业概况 - 根据Grand View Research的报告,全球临床实验室服务市场在2023年的估值为2,332亿美元,预计到2030年将以3.5%的复合年增长率增长 [7] - 推动市场增长的主要因素包括慢性疾病负担的增加、对早期诊断检查需求的增加,以及由于检测样本量增加而导致的数据管理和样本制备技术的快速进步 [7] 公司近期动态 - 今年4月,Quest Diagnostics推出了一种新的磷酸化tau 217血液生物标志物检测,用于评估阿尔茨海默病的风险 [10] - 今年3月,Quest Diagnostics完成了对PathAI的收购,以加快数字化和人工智能病理学创新的采用,提高诊断癌症和其他疾病的质量、速度和效率 [9] - 今年以来,Quest Diagnostics的股价上涨0.5%,而同期行业上涨8.1% [11]

SECAUCUS, N.J., June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG) priorities, which align with The Quest Way, the company's approach to achieving its goals. The Quest Way is comprised of the company's Purpose, strategy and culture. Quest Diagnostics Releases 2 ...

SECAUCUS, N.J. and MINNEAPOLIS, June 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and Allina Health, a leading, non-profit health care system, today announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin. "Our transaction with Allina Health will extend access to Quest's e ...

Hims & Hers Heath stock has surged 165.9% in the past year. Estimates for the company's earnings have moved upward from 18 cents to 19 cents for 2024 and from 33 cents to 35 cents for 2025 in the past seven days. Additionally, Quest Diagnostics is making headway with several promising opportunities in its robust M&A pipeline, with the recent acquisition of Lenco contributing to its first-quarter growth. Base volume growth within Hospital Lab Services will continue, courtesy of the strength in professional l ...

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call. About Quest Diagnostics Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion o ...

The transaction builds on Quest Diagnostics' leadership in oncology and subspecialized pathology services. It will support PathAI's strategy to amplify its investments in AI technology and expand its software and algorithm business. AI in pathology offers numerous advantages, including improved accuracy, increased efficiency and enhanced patient care. Furthermore, the growing demand for misdiagnosis, funding initiatives for improving patient care quality and increasing emphasis on cost control and efficienc ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in J ...

Quest Diagnostics Q1 Earnings Surpass, Margins Crash Quest Diagnostics Incorporated's first-quarter 2024 adjusted earnings per share of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure. Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter's adjusted figures. GAAP ...

SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Rob CarterRob Carter Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting the technology direction of the F ...